Sterling Investment Management LLC grew its holdings in Johnson & Johnson (NYSE:JNJ – Free Report) by 26.9% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 17,996 shares of the company’s stock after purchasing an additional 3,817 shares during the quarter. Johnson & Johnson makes up approximately 2.2% of Sterling Investment Management LLC’s holdings, making the stock its 11th biggest holding. Sterling Investment Management LLC’s holdings in Johnson & Johnson were worth $2,789,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also made changes to their positions in the company. DORCHESTER WEALTH MANAGEMENT Co boosted its position in shares of Johnson & Johnson by 8.6% in the first quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 67,618 shares of the company’s stock valued at $14,975,000 after acquiring an additional 5,327 shares during the period. Cantor Fitzgerald Investment Advisor L.P grew its stake in shares of Johnson & Johnson by 88.9% in the 1st quarter. Cantor Fitzgerald Investment Advisor L.P now owns 175,194 shares of the company’s stock worth $31,049,000 after acquiring an additional 82,429 shares in the last quarter. AMI Investment Management Inc. raised its position in shares of Johnson & Johnson by 8.8% in the first quarter. AMI Investment Management Inc. now owns 18,305 shares of the company’s stock valued at $3,244,000 after purchasing an additional 1,475 shares during the period. Equitable Holdings Inc. boosted its holdings in Johnson & Johnson by 4.9% in the 1st quarter. Equitable Holdings Inc. now owns 45,673 shares of the company’s stock valued at $8,095,000 after purchasing an additional 2,119 shares during the period. Finally, USS Investment Management Ltd boosted its position in shares of Johnson & Johnson by 2.4% during the 1st quarter. USS Investment Management Ltd now owns 860,371 shares of the company’s stock valued at $152,488,000 after acquiring an additional 20,528 shares during the last quarter. 67.57% of the stock is currently owned by institutional investors.
Johnson & Johnson Stock Up 0.5 %
JNJ opened at $171.10 on Tuesday. The firm has a market cap of $444.64 billion, a P/E ratio of 34.64, a price-to-earnings-growth ratio of 2.88 and a beta of 0.55. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.85 and a current ratio of 1.07. The business has a 50 day moving average price of $160.60 and a 200 day moving average price of $161.20. Johnson & Johnson has a twelve month low of $150.11 and a twelve month high of $181.04.
Johnson & Johnson Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Thursday, September 7th. Shareholders of record on Monday, August 28th will be given a $1.19 dividend. This represents a $4.76 dividend on an annualized basis and a yield of 2.78%. The ex-dividend date of this dividend is Friday, August 25th. Johnson & Johnson’s dividend payout ratio (DPR) is 96.36%.
Insider Buying and Selling at Johnson & Johnson
In related news, EVP Kathryn E. Wengel sold 12,465 shares of the company’s stock in a transaction dated Monday, June 12th. The shares were sold at an average price of $160.00, for a total transaction of $1,994,400.00. Following the transaction, the executive vice president now owns 65,934 shares in the company, valued at approximately $10,549,440. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 0.20% of the company’s stock.
Wall Street Analysts Forecast Growth
Several equities analysts have recently commented on JNJ shares. StockNews.com initiated coverage on shares of Johnson & Johnson in a research note on Thursday, May 18th. They set a “strong-buy” rating for the company. JPMorgan Chase & Co. increased their target price on Johnson & Johnson from $175.00 to $180.00 and gave the stock a “neutral” rating in a research note on Friday. TheStreet downgraded Johnson & Johnson from a “b” rating to a “c+” rating in a report on Friday, May 19th. Citigroup started coverage on Johnson & Johnson in a report on Tuesday, May 30th. They set a “buy” rating and a $185.00 price target on the stock. Finally, Atlantic Securities cut their price target on Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating for the company in a report on Wednesday, April 19th. Eight equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $171.60.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Featured Stories
- Five stocks we like better than Johnson & Johnson
- What Do S&P 500 Stocks Tell Investors About the Market?
- 3 Housing Stocks to Avoid as Interest Rates Rise
- How to Invest in Renewable Energy
- AMC: Is a Big Squeeze in the Coming Attractions?
- Consumer Discretionary Stocks Explained
- Rivian: A Roaring Rise Or Time To Cash Out?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
